Live Breaking News & Updates on Biocryst Pharmaceuticals Company Profile Get Rating

Stay updated with breaking news from Biocryst pharmaceuticals company profile get rating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Expected to Announce Quarterly Sales of $63.92 Million

Equities research analysts predict that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) will post $63.92 million in sales for the current quarter, according to Zacks. Five analysts have made estimates for BioCryst Pharmaceuticals’ earnings, with estimates ranging from $59.15 million to $66.95 million. BioCryst Pharmaceuticals posted sales of $49.96 million during the same quarter last […] ....

United States , Helenm Thackray , Biocryst Pharmaceuticals Company Profile Get Rating , Zacks Investment Research , Vanguard Group Inc , Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Inc , Royal Bank , Fisher Asset Management , Get Rating , Biocryst Pharmaceutical , Cryst Pharmaceuticals , Investment Research , Street Corp , Asset Management , Sarissa Capital Management , Capital Management , Cryst Pharmaceuticals Company Profile , Nasdaq Bcrx ,

$63.58 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) This Quarter

Equities research analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) to report sales of $63.58 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for BioCryst Pharmaceuticals’ earnings. The lowest sales estimate is $59.15 million and the highest is $65.34 million. BioCryst Pharmaceuticals reported sales of $49.96 million […] ....

Georgeb Abercrombie , Helenm Thackray , Morgan Stanley , Biocryst Pharmaceuticals Company Profile Get Rating , Russell Investments Group Ltd , Zacks Investment Research , Swiss National Bank , Deutsche Bank , Biocryst Pharmaceuticals , Cantor Fitzgerald , Biocryst Pharmaceuticals Inc , Royal Bank , Get Rating , Biocryst Pharmaceutical , Cryst Pharmaceuticals , Director George , Investments Group , National Bank , Cryst Pharmaceuticals Company Profile , Nasdaq Bcrx ,

BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Buy by Zacks Investment Research

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The firm currently has a $10.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target would indicate a potential […] ....

United States , Hong Kong , Georgeb Abercrombie , Helenm Thackray , Piper Sandler , Biocryst Pharmaceuticals Company Profile Get Rating , Russell Investments Group Ltd , Zacks Investment Research , Eversource Wealth Advisors , Analyst Recommendations For Biocryst Pharmaceuticals , Fairfield Bush , Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Inc , Hong Kong Ltd , Royal Bank , Get Rating , Investment Research , Cryst Pharmaceuticals , Director George , Kong Ltd , Investments Group , Cryst Pharmaceuticals Company Profile , Nasdaq Bcrx ,

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Hold" by Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) have been given a consensus recommendation of “Hold” by the thirteen brokerages that are covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price target […] ....

Hong Kong , Georgeb Abercrombie , Helenm Thackray , Biocryst Pharmaceuticals Company Profile Get Rating , Russell Investments Group Ltd , Securities Exchange Commission , Zacks Investment Research , Eversource Wealth Advisors , Analyst Recommendations For Biocryst Pharmaceuticals , Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Inc , Royal Bank , Hong Kong Ltd , Get Rating , Marketbeat Ratings , Investment Research , Exchange Commission , Director George , Kong Ltd , Investments Group , Source Wealth Advisors , Cryst Pharmaceuticals , Cryst Pharmaceuticals Company Profile , Nasdaq Bcrx ,

BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Cut to $16.00 by Analysts at Oppenheimer

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) had its price objective reduced by stock analysts at Oppenheimer from $20.00 to $16.00 in a report issued on Monday, The Fly reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price objective would suggest a potential upside of 46.39% from the stock’s current […] ....

United States , Georgeb Abercrombie , Thomson Reuter , Helenm Thackray , Piper Sandler , Biocryst Pharmaceuticals Company Profile Get Rating , Securities Exchange Commission , Analyst Recommendations For Biocryst Pharmaceuticals , Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Inc , Erp Management , Fisher Asset Management , Get Rating , Cryst Pharmaceuticals , Exchange Commission , Director George , Street Corp , Asset Management , Capital Management , Cryst Pharmaceuticals Company Profile , Nasdaq Bcrx , Lower Price Target , Oppenheimer Holdings Inc ,